Children's Hospital Medical Center, Cincinnati
cincinnatichildrens.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
661
Active
168
Phase 3
29
Total enrollment
1,404,996
Pipeline matrix
Showing 40 of 60 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Initiation of CFTR Modulator | — | — | — | — | — | 2 | |
| 129Xe | — | — | — | — | — | 2 | |
| Methylphenidate | — | — | — | — | 4 | ||
| PK-optimized oral hydroxyurea at MTD until 15 years of age. | — | — | — | — | — | 1 | |
| Guanfacine | — | — | — | — | — | 1 | |
| Hyperpolarized Xenon 129 | — | — | — | — | — | 1 | |
| Genetic Sequencing | — | — | — | — | — | 1 | |
| Quillivant XR | — | — | — | — | — | 1 | |
| 129-Xe | — | — | — | — | — | 1 | |
| Advanced Medical Therapy | — | — | — | — | — | 1 | |
| Secretin | — | — | — | — | 2 | ||
| Oxygen | — | — | — | — | 2 | ||
| Nitric Oxide | — | — | — | — | — | 1 | |
| Secondary Prophylaxis | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | 3 | ||
| Hydroxyurea | — | — | 9 | ||||
| CIML-NK Cells | — | — | — | — | — | 2 | |
| Viral specific VST | — | — | — | — | — | 2 | |
| Hyperpolarized 129 Xenon | — | — | — | — | — | 2 | |
| cyclophosphamide | — | — | — | — | 3 | ||
| Viral Specific T-cells | — | — | — | — | — | 3 | |
| Mycophenolate Mofetil | — | — | — | — | 3 | ||
| Baclofen | — | — | — | — | 2 | ||
| 2'-Fucosyllactose | — | — | — | — | — | 2 | |
| Memantine | — | — | — | — | — | 1 | |
| Roflumilast | — | — | — | — | — | 1 | |
| Gene-Corrected Macrophages administered by bronchoscopic instillation | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Alpha-proteinase inhibitor | — | — | — | — | — | 1 | |
| Mirdametinib | — | — | — | — | — | 1 | |
| Viral Specific T-cells (VSTs) Scheduled | — | — | — | — | — | 1 | |
| Viral Specific T-cells (VSTs) Treatment | — | — | — | — | — | 1 | |
| Vitamin A | — | — | — | — | — | 1 | |
| Abatacept | — | — | — | — | — | 1 | |
| phenoxymethyl penicillin | — | — | — | — | — | 1 | |
| intramuscular benzathine penicillin G (BPG) prophylaxis | — | — | — | — | — | 1 | |
| hydroxycarbamide | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| rabbit ATG | — | — | — | — | — | 1 | |
| G-CSF | — | — | — | — | — | 1 |
20 more active programs hidden
Next readouts
- 2018-07-01
- 2025-09-30
- 2025-10-28
- 2025-10-31
- 2025-12-31
- 2026-03-31
- 2026-05-01
- 2026-06-30
- 2026-07
- 2026-07
Top conditions
- Attention Deficit Hyperactivity Disorder18
- Autism Spectrum Disorder18
- Cystic Fibrosis16
- Pain15
- Sickle Cell Disease13
- Acute Kidney Injury13
- Obesity12
- Sickle Cell Anemia11
Frequently asked questions about Children's Hospital Medical Center, Cincinnati
- How many clinical trials does Children's Hospital Medical Center, Cincinnati have on ClinicalTrials.gov?
- Children's Hospital Medical Center, Cincinnati is listed as the lead sponsor on 661 clinical trials in ClinicalTrials.gov, 168 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Children's Hospital Medical Center, Cincinnati's trials are in Phase 3?
- 29 of Children's Hospital Medical Center, Cincinnati's trials are in Phase 3, spread across 60 active drug programs.
- What therapeutic areas does Children's Hospital Medical Center, Cincinnati focus on?
- Children's Hospital Medical Center, Cincinnati's most-studied conditions on ClinicalTrials.gov are Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Cystic Fibrosis, Pain, Sickle Cell Disease.
- When are Children's Hospital Medical Center, Cincinnati's next clinical trial readouts?
- Children's Hospital Medical Center, Cincinnati has 10 upcoming primary-completion readouts tracked here; the soonest is “Realizing Effectiveness Across Continents With Hydroxyurea (REACH)”, expected around 2018-07-01.